0001725160-24-000026.txt : 20240205
0001725160-24-000026.hdr.sgml : 20240205
20240205191129
ACCESSION NUMBER: 0001725160-24-000026
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240201
FILED AS OF DATE: 20240205
DATE AS OF CHANGE: 20240205
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Blackwell Kimberly
CENTRAL INDEX KEY: 0001816465
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39263
FILM NUMBER: 24597514
MAIL ADDRESS:
STREET 1: C/O ZENTALIS PHARMACEUTICALS, LLC
STREET 2: 530 SEVENTH AVENUE, SUITE 2201
CITY: NEW YORK
STATE: NY
ZIP: 10018
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Zentalis Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001725160
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 823607803
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1359 BROADWAY, SUITE 801
CITY: NEW YORK
STATE: NY
ZIP: 10018
BUSINESS PHONE: (212) 433-3791
MAIL ADDRESS:
STREET 1: 1359 BROADWAY, SUITE 801
CITY: NEW YORK
STATE: NY
ZIP: 10018
FORMER COMPANY:
FORMER CONFORMED NAME: Zentalis Pharmaceuticals, LLC
DATE OF NAME CHANGE: 20200107
FORMER COMPANY:
FORMER CONFORMED NAME: Zeno Pharma, LLC
DATE OF NAME CHANGE: 20171212
4
1
wk-form4_1707178279.xml
FORM 4
X0508
4
2024-02-01
0
0001725160
Zentalis Pharmaceuticals, Inc.
ZNTL
0001816465
Blackwell Kimberly
C/O ZENTALIS PHARMACEUTICALS, INC.
1359 BROADWAY, SUITE 801
NEW YORK
NY
10018
1
1
0
0
Chief Executive Officer
0
Common Stock
2024-02-01
4
A
0
250000
0
A
504800
D
Common Stock
2024-02-01
4
F
0
20655
11.69
D
484145
D
Stock Option (Right to Buy)
11.69
2024-02-01
4
A
0
250000
0
A
2034-01-31
Common Stock
250000
250000
D
Represents restricted stock units, each of which represent a contingent right to receive one share of common stock, and which will vest in substantially equal annual installments over a four year period following the grant date, subject to the Reporting Person's continued service with the Issuer.
Shares automatically withheld to satisfy tax obligations upon the vesting of restricted stock units previously granted to the Reporting Person.
The options will vest over four years in equal monthly installments until the options are fully vested, subject to the Reporting Person's continued service with the Issuer.
By: /s/ Melissa B. Epperly, Attorney-in-Fact for Kimberly Blackwell
2024-02-05